Endocrine/metabolic Amarna Therapeutics advances gene therapy for type 1 diabetes June 17, 2024 Amarna Therapeutics BV is advancing Nimvec AM-510 gene therapy for type 1 diabetes and has formed a scientific advisory board to guide development.Read More
Amarna secures $11M for SV40 gene therapy platform Oct. 17, 2019 By Cormac Sheridan DUBLIN – Amarna Therapeutics BV raised €10 million (US$11.1 million) in new financing to move its SV40-based gene therapy platform, SVac, toward the clinic.Read More
